Funding announcement
Curlew Bio Joins MTM's Brisbane Pod
Molecule to Medicine announces Curlew Bio as the second venture in its Brisbane Pod, with Uniquest Expansion Fund backing, to develop immunological therapies for inflammatory disease.
Company
Grey Wolf Therapeutics
Oxford
Funding history
Investors
Every investor coverage indicates participated in a round Grey Wolf Therapeutics raised.
What Grey Wolf Therapeutics bought
Companies Grey Wolf Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
People
Coverage
Stories naming Grey Wolf Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Funding announcement
Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers
Pathios Therapeutics has begun treating patients in an Australian Phase 1/2 trial of its GPR65 inhibitor PTT-4256 for advanced solid tumours. Backers to date include Canaan, Brandon Capital and Bristol Myers Squibb.
Funding announcement
Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers
Pathios Therapeutics has dosed the first patient in a Phase 1/2 trial of its GPR65 inhibitor PTT-4256, run by its Australian team; the company also cites US$58M raised to date.